| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed …
Over the last 12 months, insiders at Heron Therapeutics, Inc. have bought $0 and sold $0 worth of Heron Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Heron Therapeutics, Inc. have bought $3.31M and sold $12,506 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,387,225 shares for transaction amount of $3.58M was made by Rubric Capital Management LP (10 percent owner) on 2025‑08‑08.
| 2025-08-08 | Rubric Capital Management LP | 10 percent owner | 2.39M 1.7781% | $1.50 | $3.58M | -11.36% | ||
| 2025-08-08 | Morgan Adam | director | 1.77M 1.3158% | $1.50 | $2.65M | -11.36% | ||
| 2023-11-17 | Forbes William P | EVP, Chief Development Officer | 25,000 0.0179% | $1.09 | $27,250 | +121.10% | ||
| 2023-11-16 | Collard Craig A | Chief Executive Officer | 150,000 0.1065% | $0.92 | $137,970 | +162.87% | ||
| 2023-11-16 | Duarte Ira | EVP, Chief Financial Officer | 85,000 0.0584% | $0.89 | $75,599 | +162.87% | ||
| 2023-11-16 | Forbes William P | EVP, Chief Development Officer | 50,000 0.0363% | $0.94 | $46,995 | +162.87% | ||
| 2023-07-21 | Morgan Adam | director | 2.49M 2.0703% | $1.37 | $3.41M | +61.59% | ||
| 2022-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 1,504 0.0015% | $4.76 | $7,154 | -38.95% | |
| 2021-12-21 | Sale | Christian Waage | director | 300 0.0003% | $9.73 | $2,920 | -56.73% | |
| 2021-12-21 | Sale | Johnson Craig A | director | 250 0.0002% | $9.73 | $2,432 | -56.73% | |
| 2021-09-21 | Sale | Christian Waage | director | 600 0.0006% | $12.31 | $7,384 | -54.08% | |
| 2021-09-21 | Sale | Johnson Craig A | director | 500 0.0005% | $12.30 | $6,148 | -54.08% | |
| 2021-06-21 | Sale | Christian Waage | director | 600 0.0006% | $15.20 | $9,118 | -40.10% | |
| 2021-06-21 | Sale | Johnson Craig A | director | 500 0.0005% | $15.20 | $7,601 | -40.10% | |
| 2021-05-03 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 3,058 0.0032% | $17.66 | $54,017 | -39.34% | |
| 2021-04-15 | Sale | Christian Waage | director | 600 0.0006% | $17.51 | $10,508 | -38.97% | |
| 2021-04-06 | Sale | Johnson Craig A | director | 500 0.0005% | $17.22 | $8,610 | -33.90% | |
| 2021-01-14 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 1,654 0.0018% | $18.09 | $29,920 | -29.12% | |
| 2021-01-08 | Sale | Szekeres David Leslie | EVP, Chief Operating Officer | 7,142 0.0039% | $9.83 | $70,219 | -32.19% | |
| 2020-12-22 | Sale | MANHARD KIMBERLY | EVP, Drug Development | 20,000 0.0176% | $16.50 | $330,000 | -32.95% |
| Rubric Capital Management LP | 10 percent owner | 29100728 15.3281% | $8.28M | 1 | 0 | <0.0001% |
| Morgan Adam | director | 8753290 4.6106% | $2.49M | 2 | 0 | +25.12% |
| TANG KEVIN C | director | 5799810 3.0549% | $1.65M | 19 | 1 | +4.62% |
| Collard Craig A | Chief Executive Officer | 186496 0.0982% | $53,095.41 | 1 | 0 | +162.87% |
| RIEPENHAUSEN PETER | director | 179332 0.0945% | $51,055.82 | 2 | 0 | |
| Quart Barry D | Chief Executive Officer | 94652 0.0499% | $26,947.42 | 3 | 4 | <0.0001% |
| Duarte Ira | EVP, Chief Financial Officer | 85000 0.0448% | $24,199.50 | 1 | 0 | +162.87% |
| SPCH, LLC | Exiting 10% holder | 79238 0.0417% | $22,559.06 | 1 | 11 | |
| Forbes William P | EVP, Chief Development Officer | 79000 0.0416% | $22,491.30 | 2 | 0 | +141.99% |
| TURNBULL GREG | President & CEO | 56159 0.0296% | $15,988.47 | 3 | 0 | <0.0001% |
| GODDARD PAUL | director | 45000 0.0237% | $12,811.50 | 1 | 0 | |
| POYHONEN JOHN | EVP, Chief Commercial Officer | 18143 0.0096% | $5,165.31 | 3 | 0 | +2.43% |
| Christian Waage | director | 3200 0.0017% | $911.04 | 1 | 4 | +1.43% |
| PRENTKI RONALD J | President & CEO | 1860 0.001% | $529.54 | 2 | 0 | <0.0001% |
$17,525,882 | 60 | 5.22% | $64.7M | |
$103,288,323 | 51 | 4.78% | $56.52M | |
$24,478,755 | 37 | -34.59% | $53.59M | |
Heron Therapeutics, Inc. (HRTX) | $115,646,156 | 35 | 16.45% | $54.05M |
$390,510 | 22 | 17.68% | $58.22M |
| Increased Positions | 84 | +45.9% | 24M | +15.46% |
| Decreased Positions | 68 | -37.16% | 20M | -12.9% |
| New Positions | 25 | New | 1M | New |
| Sold Out Positions | 25 | Sold Out | 7M | Sold Out |
| Total Postitions | 199 | +8.74% | 157M | +2.57% |
| Rubric Capital Management Lp | $36,667.00 | 15.9% | 29.1M | +2M | +8.94% | 2025-09-30 |
| Adage Capital Partners Gp, L.L.C. | $12,901.00 | 5.6% | 10.24M | +2M | +30.4% | 2025-09-30 |
| Blackrock, Inc. | $12,584.00 | 5.46% | 9.99M | -114,255 | -1.13% | 2025-09-30 |
| Clearline Capital Lp | $12,238.00 | 5.31% | 9.71M | +9M | +1,033.1% | 2025-09-30 |
| Velan Capital Investment Management Lp | $11,029.00 | 4.78% | 8.75M | +2M | +25.28% | 2025-09-30 |
| Vanguard Group Inc | $10,659.00 | 4.62% | 8.46M | -11,676 | -0.14% | 2025-09-30 |
| Palisade Capital Management, Lp | $9,233.00 | 4% | 7.33M | +2M | +44.05% | 2025-09-30 |
| Tejara Capital Ltd | $5,783.00 | 2.51% | 4.59M | +72,300 | +1.6% | 2025-09-30 |
| Baker Bros. Advisors Lp | $5,357.00 | 2.32% | 4.25M | +4M | New | 2025-09-30 |
| State Street Corp | $4,601.00 | 2% | 3.65M | +189,237 | +5.47% | 2025-09-30 |